Loading the section
The price of Spyre Therapeutics, Inc. (SYRE) on October 9, 2026 is 85.69 USD, +7.25% on the day. Over 52 weeks the stock traded between 17.65 USD and 110.17 USD; the price now sits 74% of the way up that range. Over the past year the price changed by +384.67%. Market capitalization is 6.28 billion USD, rank 35 among 374 stocks of the same industry with a known capitalization.
Closing prices for 09 October 2026
Next earnings report: 03 November 2026 · Earnings calendar
Spyre Therapeutics, Inc. trades on Nasdaq under the ticker SYRE. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks SYRE has traded between 17.65 $ and 110.18 $. As of 09 October 2026 the price stood 73.54 % of the way from the 52-week low to the high.
Over one year SYRE shares rose 384.67 %; over six months they rose 67.07 %. Volatility over 90 days is 67.66 %. Dividends are not included: this is price change only, as of 09 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to book is 9.4, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 79.90 | 86.22 | 78.73 | 85.69 | 1M |
| 08 October 2026 | 79.58 | 80.91 | 77.05 | 79.90 | 2M |
| 07 October 2026 | 78.91 | 82.22 | 78.00 | 80.85 | 3M |
| 06 October 2026 | 92.08 | 92.08 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Spyre Therapeutics, Inc. (SYRE) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2025-12-31, revenue was 0 $, net income was -155.2m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:221 CRESCENT STREET BUILDING 23, SUITE 105, WALTHAM, MA, 02453, US
Spyre Therapeutics, Inc. reported revenue of 0 $ and a net loss of 179M $ over the last four quarters. Earnings per share are 1.50 $. Market capitalisation is 6.3B $.
SYRE has a return on equity of −26.75 %, above the sector median of −41.68 %. Return on assets is −23.49 %, above the sector median of −32.11 %.
| 1.2B |
| PFEPfizer, Inc. | 28.18 | +1.28 % | 929M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 79.36 |
| 80.11 |
| 4M |
| 05 October 2026 | 93.02 | 95.01 | 89.49 | 92.72 | 642,800 |
| 02 October 2026 | 91.16 | 95.27 | 90.48 | 93.19 | 1M |
| 01 October 2026 | 89.13 | 94.06 | 87.25 | 89.93 | 2M |
| 30 September 2026 | 88.64 | 95.08 | 88.00 | 89.03 | 2M |
| 29 September 2026 | 85.09 | 86.64 | 83.26 | 84.72 | 1M |
| 28 September 2026 | 84.72 | 87.12 | 84.00 | 85.79 | 1M |
| 25 September 2026 | 88.10 | 88.10 | 85.63 | 85.69 | 560,100 |
| 24 September 2026 | 87.46 | 87.46 | 82.93 | 87.09 | 2M |
| 23 September 2026 | 91.56 | 91.56 | 86.30 | 88.17 | 918,800 |
| 22 September 2026 | 91.53 | 93.58 | 89.90 | 91.97 | 1M |
| 21 September 2026 | 91.07 | 94.06 | 89.65 | 92.03 | 1M |
| 18 September 2026 | 92.82 | 93.34 | 89.85 | 90.25 | 3M |
| 17 September 2026 | 92.86 | 95.19 | 91.14 | 92.68 | 1M |
| 16 September 2026 | 91.38 | 93.07 | 90.48 | 91.17 | 1M |
| 15 September 2026 | 90.82 | 91.07 | 88.47 | 90.95 | 858,500 |
| 14 September 2026 | 90.21 | 91.40 | 89.43 | 90.80 | 1M |